A phase I–II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
Open Access
- 1 January 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (1), 109-112
- https://doi.org/10.1023/a:1008321000887
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?: Pro:European Journal Of Cancer, 1998
- Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.Journal of Clinical Oncology, 1998
- Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II studyAnnals of Oncology, 1998
- Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsAnnals of Oncology, 1998
- Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1998
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.Journal of Clinical Oncology, 1991